Will Merck pay royalty charges to John Hopkins University over Keytruda® patents?
Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion
Pembrolizumab, a monoclonal antibody marketed under the brand name Keytruda®, was Merck & Co’s highest-grossing product in FY 2023 with sales of about 25 billion
Following up on our previous post on looming biosimilar approvals over Eylea®(Aflibercept), on March 4, Biocon Biologics Limited (BBL), a subsidiary of Biocon Limited, announced
For many years, conventional medical approaches involving medication and surgery have significantly enhanced individuals’ well-being. However, certain diseases persist without a definitive cure, and these
Chimeric Antigen Receptor (CAR)-T cell therapy, a groundbreaking form of immunotherapy harnessing a patient’s own T cells to combat cancer, has undergone remarkable advancements over
Cell and gene therapies (CGTs) are generating seismic shifts in the pharmaceutical landscape by offering disease-targeting, potentially curative solutions. In recent decades, cell and gene
Secukinumab, an IL-17A antagonist, is marketed by Novartis under the brand name Cosentyx®. In 2023, Cosentyx® observed the sales of 5 billion dollars, inclusive of
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.